News
Gilead Sciences (NASDAQ:GILD) announced its second-quarter 2025 earnings and revised annual outlook after the market closed ...
Gilead's PrEP Yeztugo is set to become the pharma's star asset, with GlobalData forecasting of just under $5bn in 2031.
Adjusted earnings per share (EPS) of $2.01 beat the Zacks Consensus Estimate of $1.95 and remained flat year over year. Consequently, the stock rose 2.36% in after-market trading on Aug. 7. The stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results